Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Alembic Pharmaceuticals Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Alembic Pharmaceuticals Ltd. has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial stability despite flat recent earnings. The company’s evolving technical trend and attractive valuation relative to peers underpin this reassessment, even as long-term growth challenges persist.

Alembic Pharmaceuticals Ltd. has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Despite a modest day decline of 1.17%, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals across different timeframes, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

The 50-day moving average for Alembic Pharmaceuticals Ltd. has crossed above the 200-day moving average, signalling a golden cross on 13 Aug 2026. Yet, the stock declined 1.17% on the day of the crossover, while monthly momentum indicators remain bearish. This divergence between the moving averages and other technical signals calls for a nuanced analysis of the signal’s reliability.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest day gain of 0.33%, the stock’s technical indicators present a nuanced picture that investors should carefully analyse amid broader market conditions.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day change of 0.08%, the stock’s technical indicators present a complex picture, with weekly signals showing bullish tendencies while monthly metrics lean bearish. This divergence highlights the nuanced market sentiment surrounding the small-cap pharmaceutical player as it navigates sector challenges and broader market dynamics.

Alembic Pharmaceuticals Ltd. has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a 2.27% gain on 7 Aug 2026, the stock remains under pressure from mixed monthly trends, prompting a cautious outlook for investors in this small-cap pharmaceutical player.

Alembic Pharmaceuticals Ltd. has recently undergone a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid a challenging pharmaceutical sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now presenting a more compelling investment case relative to peers and historical averages.

Alembic Pharmaceuticals Ltd. reported a mixed performance in Q1 FY27, with consolidated net profit standing at ₹173.07 crores, representing a sequential decline of 14.62% from Q4 FY26 but a year-on-year improvement of 12.11%. The Vadodara-based pharmaceutical manufacturer, with a market capitalisation of ₹15,928 crores, delivered robust top-line growth with net sales surging 25.66% year-on-year to ₹2,149.77 crores, marking the highest quarterly revenue in the company's recent history. However, the stock has struggled to gain investor confidence, declining 16.30% over the past year whilst the broader pharmaceuticals sector rallied 17.87%, resulting in a significant underperformance of 34.17 percentage points.

Alembic Pharmaceuticals Ltd. is rated Sell by MarketsMOJO. This rating was last updated on 20 July 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 01 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 August 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Alembic Pharmaceuticals Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jul 2026. This decision follows a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some attractive valuation metrics, the downgrade reflects concerns over flat recent financial performance, deteriorating technical indicators, and subdued long-term growth prospects.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite a modest day gain of 1.97%, the stock’s technical indicators present a complex picture, with weekly signals showing bullish tendencies while monthly metrics suggest caution. This nuanced technical landscape warrants a detailed analysis for investors navigating the Pharmaceuticals & Biotechnology sector.